Such forward-looking statements include statements regarding, among other things, the expected initiation of a Phase 1 trial of RT-114 in 2025, the potential of the RaniPill platform to enable oral delivery of multiple obesity treatments and validation of such potential through preclinical data, the target product profile of semaglutide delivered via the RaniPill capsule, the novelty, convenience and attractiveness of a once-weekly oral semaglutide treatment for patients, Ranis confidence to continue building an obesity portfolio, the potential of a once-weekly oral version of semaglutide in the RaniPill capsule to deliver the same benefits as subcutaneous delivery and to impact patients lives, the sufficiency of Ranis cash reserves, and future financial performance
Available online at: 345 World Health Organization (2018)
BY REDUCING HUNGER AND INCREASING THE FEELING OF FULLNESS , Tn Pharmas GLP-1 becomes an ally during body sculpting or recomposition phases , when portion control, adherence, and consistency truly make a difference
Increasing fiber intake gradually, staying hydrated, and using probiotics may help